Pharmacology and Clinical Pharmacy Research (Aug 2017)

Effectiveness of Erythropoietin in Hypertensive Hemodialysis Patients

  • Susannia Ibrahim,
  • Ajeng Diantini,
  • Budhi Prihartanto,
  • Rudi Supriyadi

DOI
https://doi.org/10.15416/pcpr.v2i2.15245
Journal volume & issue
Vol. 2, no. 2
pp. 28 – 31

Abstract

Read online

Chronic renal failure (CRF) is one the most prevalent health problems among the elderly. On the fifth stage of CRF, the patient becomes eligible to hemodialysis. CRF-induced anemia is commonly treated with Erythropoietin (Epo). Information regarding the effectiveness of Epo in hypertensive hemodialysis patients was limited. Therefore, this study was conducted to evaluate the effectiveness of Epo in hypertensive hemodialysis patients. This study used an observational case-control analytic method. Data were retrieved from the medical records of hemodialysis patients during March-May 2014. A total of 54 participants were included. The increase of haemoglobin (Hb) in controlled hypertension was 0.6257 g/dl, while the in uncontrolled hypertension group, there was a decrease in Hb (-0.1590 g/dl). The use of Epo was more effective in hemodialysis patients with controlled hypertension. Keywords: chronic kidney disease, erythropoietin, hypertension